FINWIRES · TerminalLIVE
FINWIRES

Bank of England Leaves Key Rate Unchanged but Soaring Energy Prices Signal Policy Rethink

作者

-- The Bank of England held its key rate steady at 3.75% and reiterated its readiness to act as the ongoing war in the Middle East pushes up energy costs and creates upside risks for inflation.

The UK central bank's Monetary Policy Committee voted 8-1 in favor of a hold, with lone dissenter Chief Economist Huw Pill voting for a 25 basis-point increase to 4%, citing the "clear upward shift in risks" to achieving the BoE's 2% inflation target, according to a Thursday release. At its previous meeting in March, the committee voted unanimously to leave the bank rate unchanged.

Based on the latest data from the Office for National Statistics, the country's annual inflation rate climbed to 3.3% in March from the previous month's 3%, with the core rate, which excludes energy prices, edging down to 3.1% from 3.2%.

The BoE expects inflation to come in higher later in 2026 on the back of soaring energy prices, with "material" second-round effects posing a risk in price- and wage-setting. Specifically, the headline inflation rate is currently expected by BoE staff to decline to an average of 3.1% in the second quarter before picking up to 3.3% in the third quarter.

Given the high uncertainty around global energy prices and the potential impact on domestic inflation, the BoE set out three scenarios to determine how the war could affect the UK economy. In the worst-case Scenario C, the bank rate increases to 5.25% by the first quarter of 2027 on expectations that inflation would peak at 6.2% and remains largely above target.

"If the shock appears to be short-lived or the economy weaker, policy should place relatively more weight on avoiding unnecessary contraction in activity. If second-round effects are likely to be greater, policy should focus on returning inflation back to target more quickly," BoE Governor Andrew Bailey said.

The MPC said it will closely monitor the situation in the Middle East and that it stands ready to implement the necessary measures to ensure that inflation remains on course to meet the BoE's 2% target over the medium term.

相關文章

Sectors

產業動態:消費者

週四下午,消費性股票走高,道富消費必需品精選行業SPDR ETF (XLP)上漲1.4%,道富非必需消費品精選行業SPDR ETF (XLY)上漲0.4%。 公司方面,蘭姆韋斯頓(LW)股價上漲1.6%,此前股東Starboard Value週四致信董事會,表示公司應召開投資者日活動,並將盈利預期調整至正常水平。

$LW
Research

研究快訊:CFRA維持對Firstenergy Corp.股票的買進評等。

獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師的觀點摘要如下:我們將12個月目標股價下調1美元至55美元,本益比為20倍,基於未來12個月每股收益預期2.75美元,高於五年平均15.6倍。我們將2026年每股收益預期下修0.02美元至2.72美元,並將2027年每股收益預期下修0.01美元至2.93美元。第一季核心每股收益年增7.5%,打破了先前連續三個季度下滑的局面,我們預計在整個預測期內,成長動能將持續。 我們觀察到資料中心需求呈現正面趨勢,長期合約需求(4.3 GW)自 2026 年 2 月(4.1 GW)以來成長了 4%,自 2025 年 2 月(2.9 GW)以來成長了 47%;同時,在建專案需求(14.9 GW)自 2026 年 2012 年 125%, 2 月(6.1 GW)以來增長了一倍以上。自 2022 年以來,FE 已將基礎維運成本降低了 2 億美元以上(15%),預計 2026 年第一季將年比進一步下降約 5%,同時可靠性指標也得到提升。我們認為,FE 的成本控制、服務品質的提升以及具有競爭力的價格定位,將轉化為更有利的費率調整結果、更低的拒付風險以及更高的潛在淨資產收益率 (ROE)。

$FE
Australia

市場動態:FDA專家小組投票反對阿斯特捷利康乳癌藥物的益處

根據彭博社週四報道,美國食品藥物管理局(FDA)腫瘤藥物諮詢委員會否決了阿斯特捷利康(AZN)用於治療乳癌的候選藥物卡美司群(Camizestrant)的療效。 彭博社稱,六名委員會成員投票反對該藥物,因為他們對試驗設計及其在臨床應用中的潛在影響存在分歧。 根據一份簡報文件,該藥物試驗達到了無惡化存活期(PFS)的主要終點以及無惡化存活期2(PFS2)終點,但FDA認為PFS2不適合作為監管決策的終點。 (市場動態新聞來自與全球市場專業人士的對話。這些資訊據信來自可靠來源,但可能包含傳聞和推測。準確性無法保證。)Price: $189.60, Change: $+4.40, Percent Change: +2.37%

$AZN